Polymeric particle-based therapies for acute inflammatory diseases

ER Brannon, MV Guevara, NJ Pacifici, JK Lee… - Nature Reviews …, 2022 - nature.com
Acute inflammation is essential for initiating and coordinating the body's response to injuries
and infections. However, in acute inflammatory diseases, inflammation is not resolved but …

Chitosan and its derivatives as polymeric anti-viral therapeutics and potential anti-SARS-CoV-2 nanomedicine

RSL Tan, P Hassandarvish, CF Chee, LW Chan… - Carbohydrate …, 2022 - Elsevier
The coronavirus pandemic, COVID-19 has a global impact on the lives and livelihoods of
people. It is characterized by a widespread infection by the severe acute respiratory …

Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition

V Sanna, S Satta, T Hsiai, M Sechi - European Journal of Medicinal …, 2022 - Elsevier
Recently, a novel coronavirus, known as severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has raised global concerns, being the etiological agent of the current …

Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2

S Kamat, M Kumari, C Jayabaskaran - Journal of Controlled Release, 2021 - Elsevier
The recent outbreak of SARS-CoV-2 has forever altered mankind resulting in the COVID-19
pandemic. This respiratory virus further manifests into vital organ damage, resulting in …

[HTML][HTML] Antiviral polysaccharide and antiviral peptide delivering nanomaterials for prevention and treatment of SARS-CoV-2 caused COVID-19 and other viral …

S Homaeigohar, X Liu, M Elbahri - Journal of Controlled Release, 2023 - Elsevier
Antiviral peptides and antiviral polysaccharides can play a major role in the prevention and
treatment of emerging viral health problems. These antiviral compounds are biocompatible …

Rapamycin-based inhaled therapy for potential treatment of COPD-related inflammation: production and characterization of aerosolizable nano into micro (NiM) …

EF Craparo, M Cabibbo, C Scialabba, L Casula… - Biomaterials …, 2024 - pubs.rsc.org
Our paper describes the production and characterization of inhalable microparticles loaded
with nanoparticles for the lung administration of rapamycin (Rapa). In detail, core–shell …

[HTML][HTML] Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants

B Tu, H Wang, X An, J Qu, Q Li, Y Gao… - Acta Pharmaceutica …, 2022 - ncbi.nlm.nih.gov
As of January 27, 2022, there were 363,062,293 cases and 5,645,884 deaths from the
COVID-19 pandemic 1. The prevalent mutated strains have aggravated the global pandemic …

Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures

J Wang, Q Xie, H Song, X Chen, X Zhang… - Journal of …, 2023 - Springer
The emergence of human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
poses significant challenges to global public health. Despite the extensive efforts of …

Recent advancement in inhaled nano-drug delivery for pulmonary, nasal, and nose-to-brain diseases

Q Fu, Y Liu, C Peng, TA Muluh, U Anayyat… - Current Drug …, 2025 - benthamdirect.com
Pulmonary, nasal, and nose-to-brain diseases involve clinical approaches, such as
bronchodilators, inhaled steroids, oxygen therapy, antibiotics, antihistamines, nasal steroids …

Viral and host genetic and epigenetic biomarkers related to SARS-CoV-2 cell entry, infection rate, and disease severity

J Gaspersic, V Dolzan - Biology, 2022 - mdpi.com
Simple Summary COVID-19 emerged as a new disease with quick transmission and a high
mortality rate at the end of 2019, caused by SARS-CoV-2. Common features of the …